Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, Corbacioglu A, Herzig J, Weber D, Schrade A, Götze K, Schröder T, Lübbert M, Wellnitz D, Koller E, Schlenk RF, Gaidzik VI, Paschka P, Rücker FG, Heuser M, Thol F, Ganser A, Benner A, Döhner H, Bullinger L, Döhner K. Jahn N, et al. Among authors: schrade a. Blood Adv. 2020 Dec 22;4(24):6342-6352. doi: 10.1182/bloodadvances.2020002673. Blood Adv. 2020. PMID: 33351131 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 32812041
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, Theis F, Rücker FG, Teleanu MV, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer KT, Lübbert M, Wattad M, Götze KS, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk RF, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Kapp-Schwoerer S, et al. Among authors: schrade a. Blood. 2020 Dec 24;136(26):3041-3050. doi: 10.1182/blood.2020005998. Blood. 2020. PMID: 33367545 Free article. Clinical Trial.
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: schrade a. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: schrade a. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider I, Corbacioglu A, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Among authors: schrade a. Blood Adv. 2024 Dec 10;8(23):6067-6080. doi: 10.1182/bloodadvances.2024013758. Blood Adv. 2024. PMID: 39348668 Free PMC article.
Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).
Rücker FG, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, Wulf G, Samra MA, Teichmann LL, Lübbert M, Kühn MWM, Bentz M, Westermann J, Bullinger L, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Weber D, Schrade A, Thol F, Heuser M, Ganser A, Benner A, Döhner H, Döhner K; German‐Austrian Acute Myeloid Leukemia Study Group (AMLSG). Rücker FG, et al. Among authors: schrade a. Hemasphere. 2024 Jul 15;8(7):e123. doi: 10.1002/hem3.123. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39011127 Free PMC article. No abstract available.
Back-to-Germline (B2G) Procedure for Antibody Devolution.
Schrade A, Bujotzek A, Spick C, Wagner M, Goerl J, Wezler X, Georges G, Kontermann RE, Brinkmann U. Schrade A, et al. Antibodies (Basel). 2019 Aug 26;8(3):45. doi: 10.3390/antib8030045. Antibodies (Basel). 2019. PMID: 31544851 Free PMC article.
28 results